| OTSUKA-PHARMACEUTICAL-CO-LTD |
OTSUKA-PHARMACEUTICAL-CO-LTD |
90%
|
As of March 31, 2026, the Company had $ 4.4 million due from Otsuka Pharmaceutical Co., Ltd. ("Otsuka") related to the estimated cost sharing and reimbursement. |
| ARCT |
Arcturus Therapeutics Holdings Inc. |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| ARCT |
Arcturus Therapeutics Holdings Inc. |
72%
|
Reciprocal relationship from ARCT graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain tim… |
| JNJ |
Johnson & Johnson |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from JNJ grap… |
| KLRS |
Kalaris Therapeutics, Inc. |
72%
|
Reciprocal relationship from KLRS graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from KLRS g… |
| KOD |
Kodiak Sciences Inc. |
72%
|
Reciprocal relationship from KOD graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from KOD graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from KOD grap… |
| KOD |
Kodiak Sciences Inc. |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| LLY |
Eli Lilly and Company |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from LLY grap… |
| RGNX |
REGENXBIO Inc. |
72%
|
Reciprocal relationship from RGNX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: val of a product or impose restri… |
| SNYNF |
Sanofi |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from VRTX g… |
| AEVITAS-THERAPEUTICS-INC |
AEVITAS-THERAPEUTICS-INC |
62%
|
$ 3.0 million during the three months ended March 31, 2026. The transaction price amount allocated to unsatisfied or partially unsatisfied performance obligations as of March 31, 2026 was approximate… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
t candidates at an earlier stage of development or on less favorable terms than we would otherwise 32 choose. We cannot assure you that we will ever be profitable or generate positive cash flow from … |
| LICENSE-ARRANGEMENTS-AEVITAS-THERAPEUTICS-INC |
LICENSE-ARRANGEMENTS-AEVITAS-THERAPEUTICS-INC |
62%
|
$ 3.0 million during the three months ended March 31, 2026. The transaction price amount allocated to unsatisfied or partially unsatisfied performance obligations as of March 31, 2026 was approximate… |
| MOLECULAR-THERAPEUTICS-INC |
MOLECULAR-THERAPEUTICS-INC |
62%
|
novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherw… |
